Morning Biotech Buzz: LIXTE Lights the Way, NovaBay Pays Out, and Azitra Breaks Ground
DENVER, Colo., Aug 27, 2025 (247marketnews.com)- Wall Street opened with a burst of biotech energy this morning as multiple small-cap players made waves across oncology, dermatology, and device markets.
LIXTE’s (NASDAQ:LIXT) Oncogenic Bet Gains Traction and stole the spotlight with its co-sponsorship of a landmark global conference focused on an unconventional but promising cancer strategy: activating oncogenic signaling to kill cancer cells. The peer-reviewed journal Trends in Cancer just published highlights from the meeting (Vol. 11, No. 7), reinforcing the momentum behind LIXTE’s lead asset, LB-100, a first-in-class PP2A inhibitor.
Data presented at the conference show LB-100 may drive tumor cells into lethal hyperactivation of growth pathways and enhance immune recognition via neoantigen formation. The company’s leadership role at the event, along with expanding clinical validation, positions LIXTE at the forefront of this emerging therapeutic paradigm.
Azitra (NYSE:AZTR) Begins Phase 1/2 for ATR04-484, now that the first patient has been dosed in its Phase 1/2 trial of ATR04-484, a topical live biotherapeutic targeting EGFR inhibitor-associated rash, a common complication for oncology patients. With Fast Track designation from the FDA and a U.S. target market of roughly 150,000 patients annually, Azitra is aiming to address a quality-of-life issue that often disrupts cancer treatment.
CEO Francisco Salva called this a “milestone” in the company’s precision dermatology program, and the trial (NCT06830863) will evaluate both safety and efficacy signals like rash severity and pain. Early momentum could position AZTR as a niche leader in supportive oncology care.
NovaBay (NYSE:NBY) surprised investors with a special one-time cash dividend of $0.80 per share, a move that signals shareholder-first thinking as the company explores strategic alternatives. The dividend will be paid on September 29, 2025, to shareholders of record as of September 15.
NYSE American has designated the stock to trade with “due bills” from record date through payment date. If you’re buying or selling shares in that window, make sure to check with your broker to understand dividend rights and obligations. CEO David Lazar emphasized the move as a “commitment to returning value directly” to shareholders.
Momentum Movers to Watch
- DSS (NYSE:DSS) — Popped on investor interest as a diversified holding company with biomedical exposure.
- Rockwell Medical (NASDAQ:RMTI) — Trading volume picked up following attention on its global dialysis portfolio.
- Vir Biotechnology (NASDAQ:VIR) — Saw pre-market movement as investors revisit its dual focus on infectious disease and cancer, particularly with chronic hepatitis delta assets in the pipeline.
- Sharps Technology (NASDAQ:STSS) — Continues to attract speculative attention thanks to its smart-syringe tech and packaging solutions for pre-fillable applications.
Please go to https://247marketnews.com/lixte-biotechnology/ for further LIXT information and 247marketnews.com LIXT disclosure information.
About 24/7 Market News
As a pioneer in digital financial market media, 24/7 Market News (24/7MN) is dedicated to the swift distribution of financial market news and information. 24/7 MN incorporates comprehensive corporate communications resources and tools to engage the investment community. Visit 24/7 Market News website here.
24/7 MARKET NEWS, INC Disclaimer
Please go to https://247marketnews.com/disclaimer/ for disclaimer information.
CONTACT:
24/7 Market News
Editor@247marketnews.com